Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 8/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 9/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11295277 | 1.00 | NR3C2 (0.52) | NR3C2NR3C1MDM2MDM4PSEN1 | |
| SCHEMBL24898696 | 0.89 | PSEN1 (0.46) | NR3C2NR3C1MDM2PSEN1PSEN2 | |
| SCHEMBL4026932 | 0.84 | LMNA (0.49) | NR3C2NR3C1 | |
| SCHEMBL30369402 | 0.84 | LMNA (0.49) | NR3C2NR3C1 | |
| SCHEMBL4533837 | 0.84 | CES2 (0.45) | NR3C2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4510815 | 0.84 | NR3C2 (0.54) | NR3C2NR3C1MDM2MDM4PSEN1 | |
| SCHEMBL25689237 | 0.83 | NR3C2 (0.41) | NR3C2NR3C1PSEN1PSEN2APH1B | |
| SCHEMBL30938844 | 0.83 | NR3C2 (0.53) | NR3C2NR3C1MDM2MDM4PSEN1 | |
| SCHEMBL30938843 | 0.83 | NR3C2 (0.53) | NR3C2NR3C1MDM2MDM4PSEN1 | |
| SCHEMBL18103273 | 0.83 | MAPK1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113149961-B | Azabicyclo-substituted triazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-11-22 | — | — | CN | disclosed |